RU2014112223A - Способ профилактики и/или лечения инсулинорезистентности - Google Patents
Способ профилактики и/или лечения инсулинорезистентности Download PDFInfo
- Publication number
- RU2014112223A RU2014112223A RU2014112223/15A RU2014112223A RU2014112223A RU 2014112223 A RU2014112223 A RU 2014112223A RU 2014112223/15 A RU2014112223/15 A RU 2014112223/15A RU 2014112223 A RU2014112223 A RU 2014112223A RU 2014112223 A RU2014112223 A RU 2014112223A
- Authority
- RU
- Russia
- Prior art keywords
- rel
- insulin resistance
- alcaligenes faecalis
- eubacterium hallii
- treatment
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract 24
- 206010022489 Insulin Resistance Diseases 0.000 title claims abstract 19
- 238000000034 method Methods 0.000 title claims abstract 11
- 238000011282 treatment Methods 0.000 title claims abstract 7
- 230000002265 prevention Effects 0.000 title claims abstract 3
- 241000588813 Alcaligenes faecalis Species 0.000 claims abstract 16
- 229940005347 alcaligenes faecalis Drugs 0.000 claims abstract 16
- 241001531197 [Eubacterium] hallii Species 0.000 claims abstract 12
- 208000032928 Dyslipidaemia Diseases 0.000 claims abstract 6
- 208000017170 Lipid metabolism disease Diseases 0.000 claims abstract 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract 6
- 210000000813 small intestine Anatomy 0.000 claims abstract 6
- 238000011321 prophylaxis Methods 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fodder In General (AREA)
Abstract
1. Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. для применения при профилактике и/или лечении инсулинорезистентности и/или осложнений, связанных с инсулинорезистентностью.2. Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. для применения по п. 1, где осложнения, связанные с инсулинорезистентностью, выбраны из метаболического синдрома, дислипидемии и сахарного диабета 2 типа.3. Фармацевтическая, пищевая или кормовая композиция, включающая Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. для применения при профилактике и/или лечении инсулинорезистентности и/или осложнений, связанных с инсулинорезистентностью.4. Фармацевтическая, пищевая или кормовая композиция по п. 3, отличающаяся тем, что указанные связанные с инсулинорезистентностью состояния выбраны из метаболического синдрома, дислипидемии и сахарного диабета 2 типа.5. Способ профилактики и/или лечения инсулинорезистентности и/или осложнений, связанных с инсулинорезистентностью, у субъекта при наличии у него такой необходимости, отличающийся тем, что указанный способ включает стадию повышения уровня Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. в тонком кишечнике.6. Способ по п. 5, отличающийся тем, что уровень Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. в тонком кишечнике повышают по методу, выбранному из группы, состоящей из введения эффективного количества Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. указанному субъекту и введения эффективного количества соединения, способного повысить уровень Eubactenum hallii et rel. и/или Alcaligenes faecalis et rel. в тонком кишечнике.7. Способ по п. 5 или 6, отличающийся тем, что указанные состояния, связанные с инсулинорезистентностью, выбраны из метаболического синдрома, дислипидемии и сахарного �
Claims (10)
1. Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. для применения при профилактике и/или лечении инсулинорезистентности и/или осложнений, связанных с инсулинорезистентностью.
2. Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. для применения по п. 1, где осложнения, связанные с инсулинорезистентностью, выбраны из метаболического синдрома, дислипидемии и сахарного диабета 2 типа.
3. Фармацевтическая, пищевая или кормовая композиция, включающая Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. для применения при профилактике и/или лечении инсулинорезистентности и/или осложнений, связанных с инсулинорезистентностью.
4. Фармацевтическая, пищевая или кормовая композиция по п. 3, отличающаяся тем, что указанные связанные с инсулинорезистентностью состояния выбраны из метаболического синдрома, дислипидемии и сахарного диабета 2 типа.
5. Способ профилактики и/или лечения инсулинорезистентности и/или осложнений, связанных с инсулинорезистентностью, у субъекта при наличии у него такой необходимости, отличающийся тем, что указанный способ включает стадию повышения уровня Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. в тонком кишечнике.
6. Способ по п. 5, отличающийся тем, что уровень Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. в тонком кишечнике повышают по методу, выбранному из группы, состоящей из введения эффективного количества Eubacterium hallii et rel. и/или Alcaligenes faecalis et rel. указанному субъекту и введения эффективного количества соединения, способного повысить уровень Eubactenum hallii et rel. и/или Alcaligenes faecalis et rel. в тонком кишечнике.
7. Способ по п. 5 или 6, отличающийся тем, что указанные состояния, связанные с инсулинорезистентностью, выбраны из метаболического синдрома, дислипидемии и сахарного диабета 2 типа.
8. Фармацевтическая, пищевая или кормовая композиция, включающая Alcaligenes faecalis et rel.
9. Композиция по п. 8, которая представляет собой напиток.
10. Фармацевтическая, пищевая или кормовая композиция, включающая Alcaligenes faecalis et rel., для применения в качестве лекарственного средства.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161528931P | 2011-08-30 | 2011-08-30 | |
| NL2007319 | 2011-08-30 | ||
| US61/528,931 | 2011-08-30 | ||
| NL2007319 | 2011-08-30 | ||
| PCT/NL2012/050592 WO2013032328A1 (en) | 2011-08-30 | 2012-08-30 | Method for preventing and/or treating insulin resistance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014112223A true RU2014112223A (ru) | 2015-10-10 |
| RU2613322C2 RU2613322C2 (ru) | 2017-03-15 |
Family
ID=47756609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014112223A RU2613322C2 (ru) | 2011-08-30 | 2012-08-30 | Способ профилактики и/или лечения инсулинорезистентности |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9433650B2 (ru) |
| EP (1) | EP2753187B1 (ru) |
| JP (1) | JP6116568B2 (ru) |
| KR (1) | KR101982491B1 (ru) |
| CN (1) | CN104244733B (ru) |
| AU (1) | AU2012302364B2 (ru) |
| BR (1) | BR112014004890A8 (ru) |
| CA (1) | CA2851602C (ru) |
| DK (1) | DK2753187T3 (ru) |
| PL (1) | PL2753187T3 (ru) |
| RU (1) | RU2613322C2 (ru) |
| SG (1) | SG11201401811WA (ru) |
| WO (1) | WO2013032328A1 (ru) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10149867B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
| US10668116B2 (en) | 2014-10-31 | 2020-06-02 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| RU2737398C1 (ru) * | 2015-12-31 | 2020-11-30 | Калус Фармасьютикалс Б.В. | Способ культивирования и сохранения eubacterium hallii |
| US11583558B2 (en) | 2017-08-30 | 2023-02-21 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2613322C2 (ru) | 2011-08-30 | 2017-03-15 | Академис Медис Сентрум | Способ профилактики и/или лечения инсулинорезистентности |
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| EP2951283A4 (en) | 2013-02-04 | 2017-01-25 | Seres Therapeutics, Inc. | Compositions and methods |
| KR102222273B1 (ko) | 2013-02-04 | 2021-03-08 | 세레스 테라퓨틱스, 인코포레이티드 | 조성물 및 방법 |
| AU2014232370B2 (en) | 2013-03-15 | 2018-11-01 | Seres Therapeutics, Inc. | Network-based microbial compositions and methods |
| GB2535034A (en) | 2013-07-21 | 2016-08-10 | Whole Biome Inc | Methods and systems for microbiome characterization, monitoring and treatment |
| AU2014352643A1 (en) | 2013-11-25 | 2016-06-30 | Seres Therapeutics, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| US9956282B2 (en) | 2013-12-16 | 2018-05-01 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
| WO2016110585A1 (en) | 2015-01-09 | 2016-07-14 | Wageningen Universiteit | Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases |
| CN106974939B (zh) * | 2016-01-15 | 2020-08-25 | 深圳华大生命科学研究院 | 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用 |
| CN109069583B (zh) * | 2016-02-02 | 2021-09-21 | 肿瘤免疫股份有限公司 | 使用cd24蛋白治疗瘦素缺乏病状 |
| ES2865477T3 (es) * | 2016-02-25 | 2021-10-15 | Caelus Pharmaceuticals B V | Composiciones y métodos para la prevención y/o tratamiento de la deficiencia de vitamina B12 |
| DK3443071T3 (da) | 2016-04-11 | 2022-01-31 | Univ Wageningen | Hidtil ukendt bakterieart |
| MX2019002607A (es) | 2016-09-07 | 2019-09-18 | Univ Temple | Composiciones y metodos para el tratamiento de resistencia a la insulina. |
| AU2018209227A1 (en) * | 2017-01-19 | 2019-07-25 | Bactaviva Ab | Autologous fecal sample for use in the treatment of microbial dysbiosis |
| CN111212655A (zh) | 2017-08-14 | 2020-05-29 | 赛里斯治疗公司 | 用于治疗胆汁淤积性疾病的组合物和方法 |
| RU2020131222A (ru) * | 2018-03-02 | 2022-04-06 | Академис Медис Сентрум | Фекальный материал для профилактики или лечения аутоиммунных заболеваний |
| JP2021532097A (ja) * | 2018-07-19 | 2021-11-25 | ペンデュラム セラピューティクス， インコーポレイテッド | 微生物生着のための方法および組成物 |
| WO2021028585A1 (en) | 2019-08-14 | 2021-02-18 | Wageningen Universiteit | Bacterium comprising myo-inositol to propionate pathway |
| NL2024569B1 (en) | 2019-12-24 | 2021-09-06 | Univ Wageningen | Bacterium comprising myo-inositol to propionate pathway |
| RU2734336C1 (ru) * | 2020-03-27 | 2020-10-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ ранней неинвазивной диагностики метаболических нарушений у детей и подростков |
| EP4228665A1 (en) * | 2020-10-14 | 2023-08-23 | Dermbiont, Inc. | Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with fungi and other pathogenic microbes |
| CN113604400B (zh) * | 2021-08-26 | 2023-06-02 | 王玉莹 | 具有预防或治疗糖尿病作用的新型乳杆菌yuyingw |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| EP0796623B1 (de) * | 1996-03-20 | 2005-05-25 | Baxter Aktiengesellschaft | Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen |
| US5902578A (en) * | 1996-03-25 | 1999-05-11 | Abbott Laboratories | Method and formula for the prevention of diarrhea |
| US6227863B1 (en) | 1998-02-18 | 2001-05-08 | Donald Spector | Phonics training computer system for teaching spelling and reading |
| US6224863B1 (en) | 1998-10-30 | 2001-05-01 | University Of South Carolina | Antibiotic composition from alcaligenes species and method for making and using the same |
| EP1228769A1 (de) * | 2001-02-02 | 2002-08-07 | Jörg-Peter Prof. Schür | Symbiontisches Regenerativum |
| JP4307006B2 (ja) * | 2002-03-28 | 2009-08-05 | キリンフードテック株式会社 | 糖尿病予防剤 |
| GB0307026D0 (en) * | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
| US20080069861A1 (en) * | 2006-09-19 | 2008-03-20 | National Starch And Chemical Investment Holding Corporation | Probiotic/Non-Probiotic Combinations |
| EP2102350A4 (en) * | 2006-12-18 | 2012-08-08 | Univ St Louis | INTESTINAL MICROBIOMA AS A BIOMARKER AND THERAPEUTIC TARGET FOR TREATING OBESITY OR OBESITY-RELATED DISORDER |
| JP5350626B2 (ja) | 2007-12-20 | 2013-11-27 | キリンフードテック株式会社 | 樹状細胞活性化用組成物 |
| WO2010036876A2 (en) * | 2008-09-25 | 2010-04-01 | New York University | Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota |
| ES2588427T3 (es) * | 2009-01-23 | 2016-11-02 | Kadant Inc. | Sistema para proporcionar un desempeño mejorado de desagüe en una máquina de fabricación de papel |
| CA2776420A1 (en) * | 2009-10-05 | 2011-04-14 | Aak Patent B.V. | Methods for diagnosing irritable bowel syndrome |
| AU2011256017B2 (en) | 2010-05-18 | 2013-11-28 | Able Corporation | Method for inhibition of methane production |
| WO2012142605A1 (en) | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
| RU2613322C2 (ru) | 2011-08-30 | 2017-03-15 | Академис Медис Сентрум | Способ профилактики и/или лечения инсулинорезистентности |
-
2012
- 2012-08-30 RU RU2014112223A patent/RU2613322C2/ru active
- 2012-08-30 WO PCT/NL2012/050592 patent/WO2013032328A1/en active Application Filing
- 2012-08-30 EP EP12758652.7A patent/EP2753187B1/en active Active
- 2012-08-30 CA CA2851602A patent/CA2851602C/en active Active
- 2012-08-30 DK DK12758652.7T patent/DK2753187T3/en active
- 2012-08-30 US US14/241,851 patent/US9433650B2/en active Active
- 2012-08-30 JP JP2014528318A patent/JP6116568B2/ja active Active
- 2012-08-30 PL PL12758652T patent/PL2753187T3/pl unknown
- 2012-08-30 KR KR1020147008451A patent/KR101982491B1/ko active IP Right Grant
- 2012-08-30 AU AU2012302364A patent/AU2012302364B2/en active Active
- 2012-08-30 CN CN201280053708.2A patent/CN104244733B/zh active Active
- 2012-08-30 BR BR112014004890A patent/BR112014004890A8/pt not_active Application Discontinuation
- 2012-08-30 SG SG11201401811WA patent/SG11201401811WA/en unknown
-
2016
- 2016-07-11 US US15/207,335 patent/US9623055B2/en active Active
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10729732B2 (en) | 2012-02-29 | 2020-08-04 | Ethicon Endo Surgery, Inc. | Compositions of microbiota and methods related thereto |
| US10149870B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
| US11590176B2 (en) | 2012-02-29 | 2023-02-28 | Johnson & Johnson Consumer Inc. | Compositions of microbiota and methods related thereto |
| US10149867B2 (en) | 2012-02-29 | 2018-12-11 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
| US10842830B2 (en) | 2014-10-31 | 2020-11-24 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US10842831B2 (en) | 2014-10-31 | 2020-11-24 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US10675312B2 (en) | 2014-10-31 | 2020-06-09 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11213556B2 (en) | 2014-10-31 | 2022-01-04 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11278580B2 (en) | 2014-10-31 | 2022-03-22 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11364270B2 (en) | 2014-10-31 | 2022-06-21 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US10668116B2 (en) | 2014-10-31 | 2020-06-02 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US11931387B2 (en) | 2014-10-31 | 2024-03-19 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| RU2737398C1 (ru) * | 2015-12-31 | 2020-11-30 | Калус Фармасьютикалс Б.В. | Способ культивирования и сохранения eubacterium hallii |
| US11583558B2 (en) | 2017-08-30 | 2023-02-21 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201401811WA (en) | 2014-09-26 |
| JP6116568B2 (ja) | 2017-04-19 |
| CA2851602A1 (en) | 2013-03-07 |
| US9433650B2 (en) | 2016-09-06 |
| US20140294774A1 (en) | 2014-10-02 |
| DK2753187T3 (en) | 2019-01-28 |
| RU2613322C2 (ru) | 2017-03-15 |
| BR112014004890A8 (pt) | 2018-02-06 |
| JP2014527068A (ja) | 2014-10-09 |
| CN104244733B (zh) | 2017-07-28 |
| US20160317589A1 (en) | 2016-11-03 |
| EP2753187A1 (en) | 2014-07-16 |
| CA2851602C (en) | 2020-07-14 |
| WO2013032328A1 (en) | 2013-03-07 |
| KR20140128936A (ko) | 2014-11-06 |
| CN104244733A (zh) | 2014-12-24 |
| AU2012302364A1 (en) | 2014-04-17 |
| BR112014004890A2 (pt) | 2017-03-21 |
| PL2753187T3 (pl) | 2019-05-31 |
| US9623055B2 (en) | 2017-04-18 |
| KR101982491B1 (ko) | 2019-05-27 |
| AU2012302364B2 (en) | 2016-07-28 |
| EP2753187B1 (en) | 2018-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014112223A (ru) | Способ профилактики и/или лечения инсулинорезистентности | |
| PH12018500767A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| PH12015500688A1 (en) | Exendin-4 derivatives as dual glp1/glucagon agonists | |
| WO2013186240A3 (en) | Exendin-4 peptide analogues | |
| MX2015008077A (es) | Derivados de exendina-4 como agonistas dobles de glp1/gip o trigonal de glp1-gip/glucagon. | |
| MY176863A (en) | Ibat inhibitors for treatment of metabolic disorders and related conditions | |
| PH12016500959A1 (en) | Use of nutritional compositions having a low protein amount | |
| WO2017009236A3 (en) | New exendin-4 derivatives as selective peptidic dual glp-1 / glucagon receptor agonists | |
| WO2014004861A3 (en) | Methods of treating pediatric metabolic syndrome | |
| AR083920A1 (es) | Metodos de tratamiento de trastornos asociados con el fgf21 (factor de crecimiento de fibroblastos 21) | |
| GB201101459D0 (en) | Novel compounds and thier effects on fedding behaviour | |
| WO2011092473A8 (en) | Novel compounds and their effects on feeding behaviour | |
| WO2018169282A3 (ko) | Atpif1을 함유하는 당뇨 치료용 약학조성물 | |
| WO2015095354A3 (en) | Compositions and methods for treating fatty tissue buildup | |
| WO2016068453A8 (en) | Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component | |
| AU2010353685A8 (en) | Novel glucagon like peptide analogs, composition, and method of use | |
| EA201391063A1 (ru) | Аполипопротеин a-iv в качестве антидиабетического пептида | |
| WO2016048005A3 (ko) | 신규한 펜타디에노일 피페리딘 유도체 및 그의 용도 | |
| EA201791173A1 (ru) | Композиция, содержащая пентозу и полифенольное соединение | |
| WO2013028017A3 (ko) | 고분자량 실크 피브로인을 함유하는 혈당 및 콜레스테롤 강하용 조성물 및 그 제조방법 | |
| WO2012105816A3 (ko) | 새콩 분말 또는 이의 추출물을 포함하는 당뇨병 및 당뇨합병증 예방 및 치료를 위한 조성물 | |
| WO2012138146A3 (ko) | 돌콩의 열처리분말 또는 추출물을 유효성분으로 하는 당뇨병 및 당뇨합병증의 예방 및 치료를 위한 조성물 | |
| EA201270238A1 (ru) | Пищевая композиция, содержащая гликоген | |
| TR201900320T4 (tr) | İnsülin Direncini Önlemek Ve/Veya Tedavi Etmek İçin Usul | |
| WO2012154009A3 (ko) | 티에노피리미딘 유도체， 이의 약학적으로 허용가능한 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨 관련 질환의 또는 치료용 약학적 조성물 |